Jan 04, 2021

Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company’s Phase 3 development of simufilam for Alzheimer’s disease. AUSTIN, Texas , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

Nov 27, 2020

Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam AUSTIN, Texas , Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization ( WHO ) advised the United States Adopted Names Council (USAN) to modify the